.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,726,930

« Back to Dashboard

Details for Patent: 6,726,930

Title: Sustained release heterodisperse hydrogel systems for insoluble drugs
Abstract:A sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional cationic cross-linking agent, and a medicament having moderate to poor solubility is disclosed. In certain embodiments, the sustained release excipient is granulated with a solution or suspension of a hydrophobic polymer in an amount effective to slow the hydration of the gelling agent when the formulation is exposed to an environmental fluid. In another embodiment, the tablet is coated with a hydrophobic polymer.
Inventor(s): Baichwal; Anand R. (Wappingers Falls, NY)
Assignee: Penwest Pharmaceuticals Co. (Patterson, NY)
Filing Date:Sep 05, 2000
Application Number:09/654,691
Claims:1. A sustained release oral solid dosage form for providing an effective dose of a medicament having a solubility of less than about 10 g/l over a 24 hour period, comprising an effective amount of a medicament to render a therapeutic effect; a gelling agent comprising xanthan gum and locust bean gum in a ratio from about 1:3 to about 3:1; a pharmaceutically acceptable cationic cross-linking agent capable of cross-linking with said gelling agent and increasing the gel strength when the dosage form is exposed to an environmental fluid; and an inert pharmaceutical diluent, the ratio of said inert diluent to the total amount of said xanthan gum and said locust bean gum being from about 1:8 to about 8:1; wherein said dosage form is a tablet.

2. The dosage form of claim 1, wherein a hydrophobic material selected from the group consisting of an alkylcellulose, a hydrophobic cellulosic material, a copolymer of acrylic and methacrylic acid esters, hydrogenated vegetable oils, shellac, waxes, zein and mixtures of any of the foregoing is admixed with the medicament, the xanthan and locust bean gum, the inert diluent and the cationic cross-linking agent.

3. The dosage form of claim 1, wherein said medicament is selected from the group consisting of nifedipine, nimodipine, nivadipine, nitrendipine, nisolidipine, niludipine, nicardipine and felodipine.

4. The dosage form of claim 1, wherein said medicament is nifedipine.

5. The dosage form of claim 4, wherein the amount of nifedipine is 20 mg, 30 mg, 60 mg or 90 mg.

6. The dosage form of claim 1, wherein said cationic cross-linking agent comprises an alkali metal or an alkaline earth metal sulfate, chloride, borate, bromide, citrate, acetate, or lactate.

7. The dosage form of claim 1, wherein said cationic cross-linking agent comprises calcium sulfate.

8. The sustained release oral solid dosage form of claim 1, wherein said medicament is a dihydropyridine.

9. A sustained release oral solid dosage form for providing an effective dose of a medicament having a solubility of less than about 10 g/l over a 24 hour period, comprising an effective amount of a medicament to render a therapeutic effect; a gelling agent comprising xanthan gum and locust bean gum in a ratio from about 1:3 to about 3:1; a pharmaceutically acceptable cationic cross-linking agent capable of cross-linking with said gelling agent and increasing the gel strength when the dosage form is exposed to an environmental fluid; and an inert pharmaceutical diluent, the ratio of said inert diluent to the total amount of said xanthan gum and said locust bean gum being from about 1:8 to about 8:1; wherein said dosage form is a tablet coated with a hydrophobic coating to a weight gain from about 1 to about 20 percent of the total weight of said tablet.

10. The sustained release oral solid dosage form of claim 9, wherein a hydrophobic material selected from the group consisting of an alkylcellulose, a hydrophobic cellulosic material, a copolymer of acrylic and methacrylic acid esters, hydrogenated vegetable oils, shellac, waxes, zein and mixtures of any of the foregoing is admixed with the medicament, the xanthan gum and locust bean gum, the inert diluent and the cationic cross-linking agent.

11. The sustained release oral solid dosage form of claim 9, wherein said medicament is a dihydropyridine.

12. The sustained release oral solid dosage form of claim 9, wherein said medicament is selected from the group consisting of nifedipine, nimodipine, hivadipine, nitrendipine, nisolidipine, niludipine, nicardipine and felodipine.

13. The sustained release oral solid dosage form of claim 9, wherein said medicament is nifedipine.

14. The sustained release oral solid dosage form of claim 13, wherein the amount of nifedipine is 20 mg, 30 mg, 60 mg, or 90 mg.

15. The sustained release oral solid dosage form of claim 9, wherein said cationic cross-linking agent comprises an alkali metal or an alkaline earth metal sulfate, chloride, borate, bromide, citrate, acetate, or lactate.

16. The sustained release oral solid dosage form of claim 9, wherein said cationic cross-linking agent comprises calcium sulfate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc